drugset / Trial / NCT00927069
Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will provide data on additional therapeutic benefits in administering Adalimumab in patients with plaque psoriasis that showed an unsatisfactory response after at least 3 months of treatment with etanercept.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-09
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | — |